Zobrazeno 1 - 10
of 110
pro vyhledávání: '"Marie‐Paule Sablin"'
Autor:
Célia Dupain, Tom Gutman, Elodie Girard, Choumouss Kamoun, Grégoire Marret, Zahra Castel-Ajgal, Marie-Paule Sablin, Cindy Neuzillet, Edith Borcoman, Ségolène Hescot, Céline Callens, Olfa Trabelsi-Grati, Samia Melaabi, Roseline Vibert, Samantha Antonio, Coralie Franck, Michèle Galut, Isabelle Guillou, Maral Halladjian, Yves Allory, Joanna Cyrta, Julien Romejon, Eleonore Frouin, Dominique Stoppa-Lyonnet, Jennifer Wong, Christophe Le Tourneau, Ivan Bièche, Nicolas Servant, Maud Kamal, Julien Masliah-Planchon
Publikováno v:
BMC Biology, Vol 22, Iss 1, Pp 1-12 (2024)
Abstract Background High tumor mutational burden (TMB) was reported to predict the efficacy of immune checkpoint inhibitors (ICIs). Pembrolizumab, an anti-PD-1, received FDA-approval for the treatment of unresectable/metastatic tumors with high TMB a
Externí odkaz:
https://doaj.org/article/38a817e5035043189c5b339051b10be7
Autor:
Peter Schmid, Marie-Paule Sablin, Jonas Bergh, Seock-Ah Im, Yen-Shen Lu, Noelia Martínez, Patrick Neven, Keun Seok Lee, Serafín Morales, J. Alejandro Pérez-Fidalgo, Douglas Adamson, Anthony Gonçalves, Aleix Prat, Guy Jerusalem, Laura Schlieker, Rosa-Maria Espadero, Thomas Bogenrieder, Dennis Chin-Lun Huang, John Crown, Javier Cortés
Publikováno v:
Breast Cancer Research, Vol 23, Iss 1, Pp 1-11 (2021)
Abstract Background Xentuzumab—a humanised IgG1 monoclonal antibody—binds IGF-1 and IGF-2, inhibiting their growth-promoting signalling and suppressing AKT activation by everolimus. This phase Ib/II exploratory trial evaluated xentuzumab plus eve
Externí odkaz:
https://doaj.org/article/1117dc67dd994a8f8f4c31719c73a41f
Autor:
Célia Dupain, Julien Masliah‐Planchon, Céline Gu, Elodie Girard, Pierre Gestraud, Pauline Du Rusquec, Edith Borcoman, Diana Bello, Francesco Ricci, Ségolène Hescot, Marie‐Paule Sablin, Patricia Tresca, Alexandre deMoura, Delphine Loirat, Maxime Frelaut, Anne Vincent‐Salomon, Charlotte Lecerf, Céline Callens, Samantha Antonio, Coralie Franck, Odette Mariani, Ivan Bièche, Maud Kamal, Christophe Le Tourneau, Vincent Servois
Publikováno v:
Molecular Oncology, Vol 15, Iss 1, Pp 104-115 (2021)
High‐throughput molecular profiling of solid tumours using core needle biopsies (CNB) allows the identification of actionable molecular alterations, with around 70% success rate. Although several studies have demonstrated the utility of small biops
Externí odkaz:
https://doaj.org/article/fd5e3a2e632f4a30ae0bd88e27294874
Autor:
William Jacot, Paul Cottu, Frederique Berger, Coraline Dubot, Laurence Venat-Bouvet, Alain Lortholary, Hugues Bourgeois, Marc Bollet, Veronique Servent, Elisabeth Luporsi, Marc Espié, Severine Guiu, Veronique D’Hondt, Veronique Dieras, Marie-Paule Sablin, Etienne Brain, Souhir Neffati, Jean-Yves Pierga, Francois-Clement Bidard
Publikováno v:
Breast Cancer Research, Vol 21, Iss 1, Pp 1-9 (2019)
Abstract Background In this prospective phase 2 trial, we assessed the efficacy of trastuzumab-emtansine (T-DM1) in HER2-negative metastatic breast cancer (MBC) patients with HER2-positive CTC. Methods Main inclusion criteria for screening were as fo
Externí odkaz:
https://doaj.org/article/eb8133670a8c471b9655035877df2e22
Autor:
Paul H Cottu, Jacques Bonneterre, Andrea Varga, Mario Campone, Alexandra Leary, Anne Floquet, Dominique Berton-Rigaud, Marie-Paule Sablin, Anne Lesoin, Keyvan Rezai, François M Lokiec, Catherine Lhomme, Jacques Bosq, Alice S Bexon, Erard M Gilles, Stefan Proniuk, Veronique Dieras, David M Jackson, Alexander Zukiwski, Antoine Italiano
Publikováno v:
PLoS ONE, Vol 13, Iss 10, p e0204973 (2018)
INTRODUCTION:Onapristone is a type I progesterone receptor (PR) antagonist, which prevents PR- mediated DNA transcription. Onapristone is active in multiple preclinical models and two prior studies demonstrated promising activity in patients with bre
Externí odkaz:
https://doaj.org/article/02cc52265fd94e9ab36980e19f1d5162
Autor:
Hélène Bonsang-Kitzis, Léonor Chaltier, Lisa Belin, Alexia Savignoni, Roman Rouzier, Anne-Sophie Hamy, Marie-Paule Sablin, Florence Lerebours, François-Clément Bidard, Paul Cottu, Xavier Sastre-Garau, Marick Laé, Jean-Yves Pierga, Fabien Reyal
Publikováno v:
PLoS ONE, Vol 11, Iss 7, p e0159123 (2016)
[This corrects the article DOI: 10.1371/journal.pone.0144359.].
Externí odkaz:
https://doaj.org/article/f696ea100bd1488e82d016e80881c3c3
Autor:
Hélène Bonsang-Kitzis, Léonor Chaltier, Lisa Belin, Alexia Savignoni, Roman Rouzier, Marie-Paule Sablin, Florence Lerebours, François-Clément Bidard, Paul Cottu, Xavier Sastre-Garau, Marick Laé, Jean-Yves Pierga, Fabien Reyal
Publikováno v:
PLoS ONE, Vol 10, Iss 12, p e0144359 (2015)
BACKGROUND:Triple-negative breast cancers (TNBC) are a specific subtype of breast cancers with a particularly poor prognosis. However, it is a very heterogeneous subgroup in terms of clinical behavior and sensitivity to systemic treatments. Thus, the
Externí odkaz:
https://doaj.org/article/83ec19e3afd548d8ad9298774c6eceec
Autor:
Marc Hilmi, Maud Kamal, Sophie Vacher, Célia Dupain, Sabrina Ibadioune, Maral Halladjian, Marie Paule Sablin, Grégoire Marret, Zahra Castel Ajgal, Michèle Nijnikoff, Anne Salomon, Zakhia El Beaino, Nicolas Servant, Sylvain Dureau, Harry Sokol, Remy Nicolle, Christophe Le Tourneau, Ivan Bieche, Cindy Neuzillet
Publikováno v:
European Journal of Cancer. 183:152-161
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8a9b3a2467b190a132bd0573ba94425b
https://doi.org/10.1016/j.ejca.2023.01.024
https://doi.org/10.1016/j.ejca.2023.01.024
Autor:
Fabrice Andre, Thomas Filleron, Maud Kamal, Fernanda Mosele, Monica Arnedos, Florence Dalenc, Marie-Paule Sablin, Mario Campone, Hervé Bonnefoi, Claudia Lefeuvre-Plesse, William Jacot, Florence Coussy, Jean-Marc Ferrero, George Emile, Marie-Ange Mouret-Reynier, Jean-Christophe Thery, Nicolas Isambert, Alice Mege, Philippe Barthelemy, Benoit You, Nawale Hajjaji, Ludovic Lacroix, Etienne Rouleau, Alicia Tran-Dien, Sandrine Boyault, Valery Attignon, Pierre Gestraud, Nicolas Servant, Christophe Le Tourneau, Linda Larbi Cherif, Isabelle Soubeyran, Filippo Montemurro, Alain Morel, Amelie Lusque, Marta Jimenez, Alexandra Jacquet, Anthony Gonçalves, Thomas Bachelot, Ivan Bieche
Publikováno v:
Nature
Nature, 2022, 610 (7931), pp.343-348. ⟨10.1038/s41586-022-05068-3⟩
Nature, 2022, 610 (7931), pp.343-348. ⟨10.1038/s41586-022-05068-3⟩
Cancer progression is driven in part by genomic alterations
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e11b6e4a3a2c6123cb66ae86667e677e
https://doi.org/10.1038/s41586-022-05068-3
https://doi.org/10.1038/s41586-022-05068-3
Autor:
Ellen Kapiteijn, Padmaja Yerramilli-Rao, Caroline Emery, Adnan Derti, Leanne de Koning, Thiruvamoor Ramkumar, A. Rose Brannon, Niladri Roy Chowdhury, Sebastian Szpakowski, Alexander N. Shoushtari, Marie-Paule Sablin, F. Stephen Hodi, Gary K. Schwartz, Jason J. Luke, Richard D. Carvajal, James Larkin, Sophie Piperno-Neumann
Supplementary Table 1 shows the adverse events suspected to be study drug-related. Supplementary Table 2 shows the sequencing data availability by treatment group. Supplementary Table 3 shows the observed correlations between selected mutations/alter
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0946cd16b55249563a95620641e40f9d
https://doi.org/10.1158/1535-7163.22506985
https://doi.org/10.1158/1535-7163.22506985
